Results 111 to 120 of about 28,175 (193)

P142 | ROMIPLOSTIM AS A TREATMENT FOR CHEMOTHERAPY INDUCED THROMBOCYTOPENIA: THREE CASE REPORTS AND A LITERATURE REVIEW

Haematologica
Chemotherapy-induced thrombocytopenia (CIT) is a common hematologic complication of cancer treatment, characterized by decreased platelet counts due to the cytotoxic effects of chemotherapy on megakaryocytes.
G. Fornari, D. Cilloni, A. Ferrero, G. Valabrega   +3 more
doaj  

Comparison of Thrombocytopenia and Splenomegaly in Locally Advanced Rectal Cancer Patients Receiving Total Neoadjuvant Therapy With and Without Immunotherapy

Cancer Medicine, Volume 15, Issue 8, August 2026.
ABSTRACT Background Thrombocytopenia is a common toxicity of oxaliplatin‐based chemotherapy and may be linked to hepatic sinusoidal obstruction and splenic enlargement. In the TORCH trial, adding PD‐1 blockade to an oxaliplatin‐containing total neoadjuvant therapy (TNT) regimen improved tumor response in patients with locally advanced rectal cancer ...
Shuwen Li, Mingxu Yan, Qiong Ma, Yiqun Sun, Zhen Zhang, Lijun Shen, Juefeng Wan, Hui Zhang, Ruiyan Wu, Fan Xia, Yaqi Wang   +10 more
wiley   +1 more source

Acute Myeloid Leukemia in a Patient With Xeroderma Pigmentosum: A Case Report

Clinical Case Reports, Volume 14, Issue 8, August 2026.
ABSTRACT Acute myeloid leukemia may occur in patients with xeroderma pigmentosum at a younger age and can be associated with complex cytogenetics and poor treatment response, highlighting the importance of regular hematologic monitoring.
Mina Soryal, Mohamed Mahmoud Marey, Malak A. Hassan, Rawan El‐Sayed, Enas Kamal Abdalaziz Seyed, Ashraf Elghandour   +5 more
wiley   +1 more source

From Bone Pain to Severe Renal Symptoms: The Journey of a Patient With Multiple Myeloma and Brucellosis (Case Report)

Clinical Case Reports, Volume 14, Issue 8, August 2026.
ABSTRACT In endemic regions, markedly elevated Brucella serologic titers with a dynamic decline after treatment support true infection even in the presence of monoclonal gammopathy. Concurrent infectious and malignant processes should be considered in patients presenting with severe renal failure and overlapping systemic symptoms to avoid diagnostic ...
Maryam Ghaffari Rahbar, Tahere Zarouk Ahimahalle, Marziyeh Ghalamkari, Maedeh Olya   +3 more
wiley   +1 more source

Acute and Chronic Leukemia in Sub‐Saharan Africa: A Systematic Review

Cancer Reports, Volume 9, Issue 8, August 2026.
ABSTRACT Background The four primary subgroups of leukemia include chronic myeloid leukemia (CML), acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and chronic lymphocytic leukemia (CLL). Very little is known about the regional variation of leukemia and subtypes in sub‐Saharan Africa (SSA).
Allwell A. Ayirebi, Stephen Twumasi, Linda K. Olaga, Benedict Sackey, Daniel N. M. Antonio, Richard O. Ansah, Eugene A. Ansah, John A. Sah, Enoch O. Anto, Yvonne Anang‐Quartey, Antoinette Koomson, Angela Opoku, Godfred A. Donkor, Paulina Duah, Ama G. Boadu, Samuel Essien‐Baidoo, Wina I. O. Boadu, Lilian A. Boateng   +17 more
wiley   +1 more source

Harnessing Repurposed Drugs to Enhance Temozolomide Efficacy in Glioblastoma

Cancer Reports, Volume 9, Issue 8, August 2026.
ABSTRACT Background Glioblastoma (GB) is the most aggressive primary malignant brain tumor in adults and remains associated with poor survival despite surgical resection followed by radiotherapy and temozolomide (TMZ) chemotherapy. Intrinsic and acquired resistance to TMZ, including MGMT‐dependent DNA repair and activation of pro‐survival pathways ...
Ali Nakhaei, Atefeh Taghavi, Amir R. Afshari, Farzaneh Davoudi, Elaheh Gheybi, Mohammad Jalili‐Nik   +5 more
wiley   +1 more source

Thrombopoietin receptor agonists for chemotherapy-induced thrombocytopenia: a new solution for an old problem. [PDF]

Hematology Am Soc Hematol Educ Program, 2022
Al-Samkari H.
europepmc   +1 more source

First‐line treatment with epcoritamab in combination with bendamustine plus rituximab induces sustained remissions beyond 3 years in patients with follicular lymphoma

HemaSphere, Volume 10, Issue 8, August 2026.
Abstract First‐line (1L) bendamustine plus rituximab (BR) leads to high response rates in follicular lymphoma (FL), but maintaining durable remissions remains challenging. We report the 3‐year follow‐up from arm 3 of the phase 1b/2 EPCORE NHL‐2 trial (NCT04663347) of epcoritamab, a subcutaneously administered CD3×CD20 bispecific antibody, combined with
Umberto Vitolo, Lorenzo Falchi, Per‐Ola Andersson, Marcel Nijland, Fritz Offner, Sylvia Snauwaert, Jacob H. Christensen, Michael R. Clausen, Alexander Fosså, Pilar G. Prieto, Eliza A. Hawkes, Judit M. Jørgensen, Yasmin H. Karimi, Catharina Lewerin, Joost S. P. Vermaat, Björn E. Wahlin, Poliana Patah, Christopher Morehouse, Malene Risum, Zhu Li, Jennifer Marek, Joshua D. Brody   +21 more
wiley   +1 more source

Venetoclax plus azacitidine, low‐dose cytarabine, aclarubicin, and G‐CSF (VA‐CAG regimen) for newly diagnosed young patients with acute myeloid leukemia: A prospective, multicenter, single‐arm Phase II clinical trial

HemaSphere, Volume 10, Issue 8, August 2026.
Abstract We conducted a prospective, multicenter, Phase II study to evaluate the safety and efficacy of venetoclax/azacitidine/low‐dose cytarabine/aclarubicin/granulocyte colony‐stimulating factor (G‐CSF) (VA‐CAG) in young patients with newly diagnosed acute myeloid leukemia (ND‐AML). The VA‐CAG regimen included venetoclax (100 mg/day, Days 1–2; 200 mg,
Xiaoping Li, Qiurong Zhang, Xiaoyan Li, Lin Liu, Yonglin Shen, Yu Li, Lihui Peng, Chaoyang Zhou, Chie Qiu, Zhongtao Yuan, Shiqian Hou, Youcheng Wang, Lihua Zhang, Jingqiong Li, Liang Zhao, Qiuyuan Tang, Zucong Chen, Jing Feng, Xuejuan Zhang, Guoxiu Bao, Kui Zhang, Renpeng Zhang, Shiqi Li, Yingnian Chen, Jianhua Rao, Yancheng Dong, Dingsong Zhang, Yueyuan Wang, Aifang Li, Xi Ye, Lei Lei, Jiao Chen, Sufen Xu, Yanling Jin, Chaoen Zheng, Yang Liang, Sanbin Wang   +36 more
wiley   +1 more source

P35 | Adverse reaction to rituximab: an unusual case of drug- induced trombocytopenia

Italian Journal of Medicine
Premises: Chemotherapy-induced thrombocytopenia is a common complication. Rituximab, an anti-CD20 monoclonal antibody, induces lysis of B cells only. We describe an acute thrombocytopenia induced by rituximab associated with anaphylaxis and acute kidney
doaj   +1 more source